Safety and IOP-Lowering Effects of WB007

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a 2-part study. Part 1 will look at up to 3 formulations of WB007 ophthalmic solution following a single dose in one eye. Part 2 will look at up to 2 formulations of WB007 (to be selected based on results from Part 1) in both eyes compared with timolol 0.5% for 14 days.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Whitecap Biosciences, LLC
• Treatments: Maleic acid; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Ocular hypertension or primary open-angle glaucoma in each eye

Exclusion Criteria:

• History of orthostatic hypotension

• Any active ocular disease

• Anticipated wearing of contact lenses during study

• Contraindication to pupil dilatation